Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL
Clinical trial NCT00543114 · TERMINATED
Trial details
- NCT number
- NCT00543114
- Sponsor
- Dana-Farber Cancer Institute
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2007-10-01
- Primary completion
- 2009-06-01
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.